See the latest news and media coverage for LENZ Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Pharmaceutical company developing ophthalmic treatments
lenz-tx.comLast updated
In short: LENZ Therapeutics expanded its global footprint and product reach through licensing deals, celebrity partnerships, and regulatory filings.
Total revenue reached $5.5 million, driven by VIZZ product sales and license agreements. The company expanded into new international markets and launched telehealth and TV advertising campaigns.
The platform provides online evaluations, e-pharmacy fulfillment, and home delivery. It is promoted with a national TV ad campaign featuring Sarah Jessica Parker to accelerate patient access.
Everest acquired rights from Corxel via asset purchase agreement, with NDA submitted in September 2025 and approval anticipated in Q1 2027. LENZ eligible for up to $85 million in milestones plus royalties.
The MHRA submission follows EMA validation and marks the sixth ex-U.S. regulatory filing, supporting global expansion for the presbyopia eye drop.
The analyst fair value estimate for LENZ Therapeutics has shifted from US$32.00 to about US$26.83...
Lenz Therapeutics (LENZ) stock dips as Bank of America downgrades the firm to Neutral on a...
SAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. ("Arrotex") today announced an...
Investing.com - Piper Sandler downgraded LENZ Therapeutics Inc (NASDAQ:LENZ) to Neutral from Overweight on Tuesday and lowered its price target to $12.00 from $39.00, citing...
Track LENZ Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to LENZ Therapeutics and other trending companies.